title: Fluorescent in situ hybridization study of c-myc oncogene copy number in prostate cancer.
abstract: We previously conducted a study of 88 cases of prostate cancer in an attempt to identify potential prognostic biomarkers that can distinguish aggressive cases that must be treated immediately. Prostate cancer is a serious disease affecting men worldwide and compromises the quality of life of its patients. Biomarkers studied included chromosome 7 trisomy, chromosome 8 trisomy, and HER-2/neu oncogene amplification. These biomarkers were initially studied because trisomy 8 and oncogene amplification of the HER-2/neu gene have been reported in many other cancers, including those studied in this laboratory. In view of the fact that HER-2/neu amplification was not found to play a prominent role in the group of prostate cancer specimens that we studied, an exploration of other biomarkers was felt to be warranted. Thus, we began a pilot study of c-myc oncogene copy number in prostate cancer using the same protocol for fluorescent in situ hybridization and a direct-labeled SpectrumOrange LSI c-myc probe (Vysis, Inc., Downers Grove, IL) on formalin-fixed, paraffin-embedded tissue. From a total of 36 cases of prostate cancers successfully analyzed, we found 11 (31%) tumors exhibiting 3 or more positive signals for c-myc in 15% or more of the cells. Of these, only 7 tumors (19% of the total cases studied) had >/=3 signals in 20% or more of the cells. No case had >/=3 signals in 25% or more of the cells. Compared to other molecular probes tested, the c-myc signals were more faint and the quality of the preparation was less optimal than other tumor specimens that we previously studied. Based on the information available thus far, we conclude that an increased copy number in c-myc oncogene copy number was not a prominent finding in our cohort of prostate cancer patients.
authors.affiliation: KRAM Corporation, Barrington, Rhode Island, 02806, USA.
authors.forename: H F
authors.initials: HF
authors.lastname: Mark
authors.forename: M
authors.initials: M
authors.lastname: Samy
authors.forename: K
authors.initials: K
authors.lastname: Santoro
authors.forename: S
authors.initials: S
authors.lastname: Mark
authors.forename: D
authors.initials: D
authors.lastname: Feldman
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics* / Q000473:pathology / Q000601:surgery; D000368:Aged; D004273:DNA, Neoplasm / Q000032:analysis; D018628:Gene Dosage; D016259:Genes, myc; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000473:pathology / Q000601:surgery; D016271:Proto-Oncogene Proteins c-myc / Q000235:genetics*
chemical_list: D004273:DNA, Neoplasm; D016271:Proto-Oncogene Proteins c-myc